MedTrace Logo

Ulipristal for Endometriosis-related Pelvic Pain

NCT02213081 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-05-16

Study results available
· View outcomes & findings →

Summary

The aim of this research is to assess the benefit of a medication (ulipristal) for alleviation of symptoms in women with chronic, endometriosis-related pelvic pain.

Conditions

  • Endometriosis

Interventions

DRUG

Ulipristal

Patient will take 15mg every other day, or every 4 days per week.

Sponsors & Collaborators

Principal Investigators

  • Serdar Bulun · Northwestern University, Northwestern Memorial Hopsital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-11-30
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02213081 on ClinicalTrials.gov